Literature DB >> 25953662

Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis.

Austin H Nguyen1, Elliott J Miller1, Christopher S Wichman2, Ilya G Berim3, Devendra K Agrawal4.   

Abstract

The diagnostic value of tumor markers, carcinoembryonic antigen (CEA), cancer antigen (CA) 15-3, CA 19-9, CA 125, cytokeratin fragment (CYFRA), and neuron-specific enolase (NSE) in pleural fluid to differentiate between benign and malignant pleural effusion (MPE) has not yet been clearly established. A review of English language studies using human subjects was performed. Sensitivity and specificity values of the chosen tumor markers were pooled using a random effects model to generate hierarchical summary receiver operator curves to determine the diagnostic performance of each tumor marker. A total of 49 studies were included in the final analysis. Pooled sensitivity and specificity values for chosen tumor markers for diagnosing MPE are as follows: CEA, 0.549 and 0.962; CA 15-3, 0.507 and 0.983; CA 19-9, 0.376 and 0.980; CA 125, 0.575 and 0.928; CYFRA, 0.625 and 0.932; NSE, 0.613 and 0.884. The use of individual tumor markers in diagnosing MPE has many benefits (cost, invasiveness, and so forth). Although these tumor markers exhibit high specificity, the low sensitivity of each marker limits the diagnostic value. We conclude that tumor markers used individually are of insufficient diagnostic accuracy for clinical use. Tumor markers used in various combinations or from serum may have some potential worth further investigation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953662      PMCID: PMC4608857          DOI: 10.1016/j.trsl.2015.04.006

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  26 in total

1.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

Review 2.  [Cyfra 21-1--new marker for lung cancer].

Authors:  E Luczak; M Faber; A Chciałowski
Journal:  Pneumonol Alergol Pol       Date:  1996

Review 3.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

4.  Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method.

Authors:  B Littenberg; L E Moses
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

5.  Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion.

Authors:  Chi-De Chen; Chih-Liang Wang; Chia-Jung Yu; Kun-Yi Chien; Yi-Ting Chen; Min-Chi Chen; Yu-Sun Chang; Chih-Ching Wu; Jau-Song Yu
Journal:  J Proteome Res       Date:  2014-05-14       Impact factor: 4.466

Review 6.  Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.

Authors:  Q-L Liang; H-Z Shi; X-J Qin; X-D Liang; J Jiang; H-B Yang
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

7.  Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.

Authors:  David Shitrit; Boris Zingerman; Ariella Bar-Gil Shitrit; Dekel Shlomi; Mordechai R Kramer
Journal:  Oncologist       Date:  2005-08

8.  Neuron-specific enolase is produced by neuroendocrine tumours.

Authors:  F J Tapia; J M Polak; A J Barbosa; S R Bloom; P J Marangos; C Dermody; A G Pearse
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

9.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

10.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.

Authors:  Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell
Journal:  Thorax       Date:  2014-08-06       Impact factor: 9.139

View more
  23 in total

Review 1.  Biochemical Analysis of Pleural Fluid and Ascites.

Authors:  Sa Paul Chubb; Robin A Williams
Journal:  Clin Biochem Rev       Date:  2018-05

2.  Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.

Authors:  Mei Feng; Jing Zhu; Liqun Liang; Ni Zeng; Yanqiu Wu; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Oncol       Date:  2016-12-18       Impact factor: 3.402

3.  Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis.

Authors:  Yan-Qiu Han; Lei Zhang; Li Yan; Pei-Heng Ouyang; Peng Li; Zhi-De Hu
Journal:  Ann Transl Med       Date:  2019-10

4.  Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.

Authors:  Xin Fan; Yanqing Liu; Zhigang Liang; Shanshan Wang; Jing Yang; Aihua Wu
Journal:  Pathol Oncol Res       Date:  2022-04-20       Impact factor: 2.874

5.  Diagnostic Performance of Bronchoalveolar Lavage Fluid CD4/CD8 Ratio for Sarcoidosis: A Meta-analysis.

Authors:  Yongchun Shen; Caishuang Pang; Yanqiu Wu; Diandian Li; Chun Wan; Zenglin Liao; Ting Yang; Lei Chen; Fuqiang Wen
Journal:  EBioMedicine       Date:  2016-04-21       Impact factor: 8.143

6.  Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.

Authors:  José M Porcel; Aureli Esquerda; Montserrat Martínez-Alonso; Silvia Bielsa; Antonieta Salud
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis.

Authors:  Yongchun Shen; Caishuang Pang; Konglong Shen; Yanqiu Wu; Diandian Li; Chun Wan; Zenglin Liao; Ting Yang; Lei Chen; Fuqiang Wen
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

8.  Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid.

Authors:  Zahra Rahemi; Abdolreza Javadi; Behrang Kazeminejad; Abdolali Ebrahimi; Houman Vosough; Afsoon Taghavi; Shahriar Dabiri
Journal:  Iran J Pathol       Date:  2021-05-09

9.  Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion.

Authors:  Yi Shan; Hui Ding; Junjie Lu; Zhijun Ge; Yongfei Tan
Journal:  Oncotarget       Date:  2017-11-22

10.  Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.

Authors:  Nick Beije; Jaco Kraan; Michael A den Bakker; Alexander P W M Maat; Cor van der Leest; Robin Cornelissen; Ngoc M Van; John W M Martens; Joachim G J V Aerts; Stefan Sleijfer
Journal:  Cell Oncol (Dordr)       Date:  2017-06-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.